z-logo
open-access-imgOpen Access
Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function
Author(s) -
Sharon Lim,
Tzuen Yih Saw,
Min Zhang,
Matthew R. Janes,
Kassoum Nacro,
Jeffrey Hill,
An Qi Lim,
Chia-Tien Chang,
David A. Fruman,
David A. Rizzieri,
SooYong Tan,
Hung Fan,
Charles Chuah,
S. Tiong Ong
Publication year - 2013
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1301838110
Subject(s) - myeloid leukemia , stem cell , cancer research , haematopoiesis , cancer stem cell , leukemia , biology , hematopoietic stem cell , immunology , microbiology and biotechnology
Significance Cancer stem cells (CSCs) frequently acquire the ability to self-renew and persist in their hosts by coopting normal stem cell programs. Blast crisis (BC) chronic myeloid leukemia is a prototypic example, as the acquired activation of β-catenin signaling that enables BC CSC function is also important in normal hematopoietic stem cell maintenance. In identifying eIF4E phosphorylation by the MNK kinases as a necessary step in β-catenin activation in BC CSCs, but not normal hematopoietic stem cells, we define a therapeutic target in BC. Our studies suggest that clinical trials with MNK kinase inhibitors are warranted in BC chronic myeloid leukemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom